1
2
3
4   **Real-World Effectiveness of Digital Therapeutics for Hypertension Management**
5
6
7   Akihiro Nomura[1-4], Shuntaro Sato[5], Yusuke Takagi[6,7], Tomoyuki Tanigawa[6],
8   Masayuki Takamura[1], Koichi Node[8], Kazuomi Kario[9]
9
10
[1]Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa,
Japan
[2]Division of Convergence Science, Kanazawa University Graduate School of Frontier Science Initiative, Kanazawa,
Japan
[3]Frontier Institute of Tourism Sciences, Kanazawa University, Kanazawa, Japan
[4]Noto Resilience and Revitalization Center, Kanazawa University, Kanazawa, Japan
[5]Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
[6]CureApp Inc., Tokyo, Japan
[7]Teikyo Academic Research Center, Teikyo University, Tokyo, Japan
[8]Department of Cardiovascular Medicine, Saga University, Saga, Japan
[9]Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine,
Tochigi, Japan
23
24
25
26   **Corresponding author:**
27   Akihiro Nomura, MD, PhD
28   Professor
29   Division of Convergence Science
30   Kanazawa University Graduate School of Frontier Science Initiative
31   Kakuma-machi, Kanazawa, Ishikawa, 920-1192, Japan
32   Email: anomura@med.kanazawa-u.ac.jp

Abstract

Background: Hypertension is a major modifiable risk factor for cardiovascular disease that affects approximately 43 million people in Japan. Although lifestyle modifications are recommended as first-line interventions, their implementation within clinical settings remains challenging. Following regulatory approval of a digital therapeutic (DTx) for hypertension in Japan in 2022, we evaluated its real-world effectiveness, particularly among demographics previously excluded from clinical trials.

Methods: Practice-based, real-world data from patients prescribed CureApp HT between September 2022 and December 2023 were analyzed. Participants who were ≥18 years old and had at least one baseline morning blood pressure recording were included and followed for 24 weeks. The primary outcome was a change in the morning home systolic blood pressure (SBP), whereas the secondary outcomes included other blood pressure parameters and app usage metrics such as individual app engagement proportion and in-app program durations. Statistical analyses included multivariable linear regression models to evaluate between-subgroup differences while adjusting for baseline characteristics including baseline SBP levels and seasonal timing of DTx initiation.

Results: Among the 2038 eligible patients, mean age was 55.8 ± 11.4 years and 48.8% were female. Morning home SBP decreased from baseline at week 12 (−4.8 mmHg; 95% confidence interval [CI], −5.3 to −4.4) and week 24 (−6.0 mmHg; 95% CI, −6.6 to −5.4), with corresponding reductions in other blood pressure parameters. Consistent benefits were observed across subgroups, including older adults (≥65 years; −6.6 mmHg at week 24) and those on antihypertensive medication (−5.2 mmHg) who had previously been excluded from clinical trials. Multivariable analyses identified baseline SBP and seasonal timing of DTx initiation as determinants of treatment response, with smaller reductions having been observed with summer initiation than with spring initiation. Furthermore, good app usage metrics, including high individual app engagement and reduced in-app program durations, promoted increased SBP reductions.

Conclusions: Real-world evidence demonstrates that a DTx designed for individuals with hypertension effectively reduced blood pressure across diverse patient populations, with baseline SBP, seasonal factors, and patient engagement significantly influencing treatment efficacy. These findings provide important clinical insights for optimizing daily digital hypertension management.

Introduction

Hypertension, defined as an elevation in the systolic blood pressure (SBP), has been identified as a major modifiable risk factor that greatly contributes to the global prevalence of cardiovascular illnesses.[1] In fact, experts estimate that around 43 million people in Japan suffer from hypertension.[2] Around 90% of all cases have essential hypertension due to the critical involvement of various lifestyle factors, such as excessive salt intake, obesity, and inactivity, in its progression.[2] Current guidelines recommend that all hypertensive patients initially undergo lifestyle adjustments.[3] However, the poor persistence of these lifestyle modifications and the complexity of offering individualized lifestyle guidance within the constraints of outpatient consultation times have created much difficulties.[2] Long-term maintenance of lifestyle adjustments, particularly reduced salt intake, has been proven to be quite difficult,[4] underscoring the need for more potent techniques of lifestyle intervention.

To address these problems, digital therapeutics (DTx) applications for hypertension have been developed with the aim of offering ongoing lifestyle advice, including diet and exercise, to enhance the effectiveness of lifestyle guidance beyond the limitations of outpatient settings.[5,6] The recent HERB-DH1 randomized controlled trial on patients with untreated essential hypertension[7] showed that using the DTx app (CureApp HT, CureApp, Inc., Tokyo, Japan) significantly reduced blood pressures over 24 h at home and at the office and was cost-effective.[8] Since the approval and reimbursement of DTx for hypertension in Japan in September 2022, over a thousand patients with essential hypertension have been treated using the app. However, limited knowledge has been available regarding its effectiveness in clinical settings, especially the impact of patient age and the use of existing medications.

The current study therefore aimed to elucidate the real-world effectiveness of DTx for hypertension management by evaluating blood pressure changes among patients prescribed the DTx app for hypertension using a practice-based real-world data (RWD) cohort. Moreover, we expanded our study to encompass demographics previously excluded from the HERB-DH1 trial, specifically older adults aged 65 and above and those taking antihypertensive medication at the time of DTx prescription. This strategy allows for a thorough assessment of the DTx app's effectiveness across a larger patient population.

Methods

Overview

Deidentified practice-based RWD for CureApp HT were used to evaluate blood pressure trends in consecutive patients over a period of up to 6 months (**Figure 1**). Our group safely stores these data in accordance with health information privacy guidelines. Our study protocol was approved by the Medical

Ethics Committee of Kanazawa University and was registered with the UMIN Clinical Trials Registry

(UMIN ID: UMIN000052169).

CureApp HT

In 2022, CureApp HT, a DTx app for hypertension management, received regulatory approval and

insurance coverage in Japan. This novel therapeutic modality integrates mobile app technology into

outpatient hypertension care. Detailed information about the DTx app has been presented previously.[5,7,9]

In brief, this app provides continuous support for hypertension management through lifestyle

modifications between clinic visits[5] and aims to optimize nonpharmacological interventions as

recommended by existing guidelines[3,10,11] by educating patients on hypertension and promoting six

evidence-based lifestyle modifications, namely salt reduction, weight management, exercise, alcohol

moderation, sleep improvement, and stress management.[5] The 6-month program consists of three phases:

education about hypertension management (Step 1), guided lifestyle interventions (Step 2), and self-

directed goal setting for behavioral maintenance (Step 3).[5,7]

Criteria for inclusion and exclusion

Patients aged ≥18 years included in the CureApp HT practice-based RWD cohort were enrolled. Eligible

participants were prescribed CureApp HT between September 2022 and December 2023 and required to

have at least one recorded morning blood pressure during week 1 (defined as the baseline) for subsequent

analyses. Patients who lacked baseline body mass index (BMI) data or showed no app usage following

the prescription were excluded. All participants were followed for 24 weeks after the prescription,

corresponding to the redemption period for DTx in Japan (**Figure 1**).

Outcomes

The primary outcome was changes in home SBP from baseline to weeks 12 and 24. Secondary outcomes

included changes in morning diastolic blood pressure (DBP), evening SBP, and DBP from baseline to

weeks 12 and 24. The overall DTx retention rate was defined as the study-wide percentage of patients

who entered their blood pressure values into the app at least once during the specified week (week 12 or

24). We also evaluated the proportions at which each hypertension guideline-recommended blood

pressure threshold was achieved [(1) SBP <135 mmHg and DBP <85 mmHg based on the 2023

guidelines by the European Society of Hypertension (ESH)[11]; (2) SBP <130 mmHg and DBP <80 mmHg

based on the 2017 guidelines by the American College of Cardiology (ACC) and American Heart

Association (AHA)[12]; and (3) SBP <125 mmHg and DBP <75 mmHg based on the 2019 guidelines by the

Japanese Society of Hypertension (JSH) [3]] at weeks 12 and 24.

Additionally, the following app usage metrics were obtained: individual app engagement

proportion, duration in the Step 1 program, and duration in the Step 2 program. Individual app

engagement proportion was calculated as the percentage of days on which blood pressure was measured

and input by the patient from day 1 to their last day of app usage. Step 1 phase duration was defined as

the number of days from the start of app usage to the beginning of Step 2, whereas Step 2 phase duration

was defined as the interval between the start of Step 2 and the start of Step 3.

Practice-based real-world data extraction

As of September 2024, deidentified baseline profiles and blood pressure readings for all candidate

patients were obtained from the cohort database. The prescription date was considered as day 1. Data

were censored on the final day of blood pressure measurement or at the conclusion of follow-up (168

days, equivalent to 24 weeks). Weekly average blood pressure measurements were obtained using a 7-day

arithmetic mean of each blood pressure type from weeks 2 to 24. The baseline SBP for week 1 was

calculated by averaging the 6-day SBP readings from days 2 to 7, omitting measurements on day 1 as

previously mentioned.[13] Abnormal values, identified as BMI <10 or >100 and weekly average SBP of

<60 or >240 mmHg, were omitted and designated as not applicable. The database did not impute missing

or not applicable values. In the RWD cohort, medication usage was defined based on the app user's

declaration of "the use of medication" up until July 26, 2023, and "the use of antihypertensive

medication" subsequent to July 27, 2023, as stated on the questionnaire within the DTx app.

Statistical analysis

For baseline characteristics, continuous variables were presented as means with standard deviations or

medians with interquartile ranges, depending on the data distribution, whereas categorical variables were

reported as the numbers with proportions. The primary and secondary endpoints were examined using the

mean with 95% confidence intervals (CI) based on the *t-distribution*.

Subgroup analyses for changes in home morning SBP from baseline to weeks 12 and 24 were

conducted based on age (<65 or ≥65 years), sex (male or female), BMI (<25 or ≥25 kg/m^2), salt check-

sheet score (<14 or ≥14 points), medication status (yes, no, or unknown), baseline morning home SBP

(<120, 120–130, 130–140, 140–150, or ≥150 mmHg), and season of DTx initiation (spring, March to

May; summer, June to August; autumn, September to November; or winter, December to February).[14]

During subgroup analyses, between-subgroup differences were evaluated using multivariable linear

regression models, with each model adjusting for all baseline characteristics (age, sex, BMI, salt check-

sheet score, medication status, baseline morning home SBP category, and season of DTx initiation)

except the variable under investigation. Additionally, Pearson's correlation coefficients were calculated to

evaluate relationships between morning home SBP at baseline and those at weeks 12 and 24.

For analyses of app usage metrics, we categorized individual app engagement proportion into a

binary outcome (good or poor), with the threshold for "good" being set at 71.4%. This aligns with the

reimbursement criterion for the use of DTx in hypertension management in Japan, which requires blood

pressure readings to be taken at least five times per week (equivalent to 5 out of 7 days, or 71.4%).

Between-group differences were assessed based on the following thresholds: (1) individual app

engagement proportion (≥71.4% vs. <71.4%); (2) duration in Step 1 (≥30 vs. <30 days); and (3) duration

in Step 2 (≥60 and <60 days). Between-group differences were also evaluated using multivariable linear

regression models to adjust for age, sex, BMI, salt check-sheet score, medication status, baseline morning

home SBP, and season of DTx initiation. Data visualization and analyses were performed using R version

4.4.2, which was developed by the R Foundation for Statistical Computing in Vienna, Austria, and

included the use of R packages including "dplyr," "tidyverse," "car," "ggplot2," "grid," and

"forestploter."

Results

The baseline characteristics of eligible patients are displayed in **Table 1**. The median follow-up duration

was 168 days (interquartile range [IQR], 137–168 days). The sample comprised 48.8% females, with a

mean age of 55.8 ± 11.4 years (range, 18–92 years). Baseline home blood pressure readings were 133.5 ±

13.5 mmHg (morning SBP), 86.2 ± 10.3 mmHg (morning DBP), 129.4 ± 14.0 mmHg (evening SBP), and

81.6 ± 11.1 (evening DBP). Regarding the seasonal distribution of DTx prescription, the number of

patients enrolled during autumn and winter was twice that enrolled during spring and summer, reflecting

the study enrollment period (from September 2022 to December 2023).

Changes in blood pressure from baseline

For our primary analysis, we first evaluated changes in morning home SBP from baseline in the practice-

based RWD group. Changes in morning home SBP from baseline were −4.8 mmHg (CI, −5.3 to −4.4)

and −6.0 mmHg (CI, −6.6 to −5.4) at weeks 12 and 24 (**Figure 2**). We also assessed variations in morning

home DBP, evening home SBP, and DBP (**Figures S1–S3**). At week 24, changes in each morning home

DBP, evening home SBP, and DBP were −4.3 mmHg (CI, −4.7 to −3.8), −5.7 mmHg (CI, −6.4 to −5.1),

and −4.1 mmHg (CI, −4.6 to −3.6), respectively. Furthermore, the overall DTx retention rates were 80.7%

(CI, 78.8–82.6) and 65.9% (CI, 63.4–68.4) at weeks 12 and 24.

Additionally, we assessed achievement proportions based on each guideline-recommended blood

pressure threshold (**Figure S4**). At week 24, the achievement proportions based on ESH 2023, ACC/AHA

2017, and JSH 2019 were 56.4%, 33.8%, and 15.9% for morning home blood pressure and 73.5%, 56.8%,

and 33.1% for evening home blood pressure.

Variations in morning home SBP reduction across different subgroups

Next, we assessed morning home SBP variations across the subgroups at week 12 (**Figure 3A)** and 24

(**Figures 3B and S5–S9**). Consistent SBP reduction was observed across other subgroups, particularly

among patients aged ≥65 years and those on antihypertensive medication upon DTx initiation at both

weeks 12 and 24. These findings demonstrate therapeutic benefits in two populations previously excluded

from the HERB-DH1 trial: (1) patients aged ≥65 years (change from baseline at week 24, −6.6 mmHg

[CI, −7.9 to −5.2]; adjusted difference vs. <65 years, 0.18 [CI, −1.1 to 1.5]) and (2) those on medication at

baseline (−5.2 mmHg [CI, −6.2 to −4.2; adjusted difference vs. no medication, 0.74 [CI, −0.57 to 2.0]).

Notably, baseline morning home SBP and seasonal timing of DTx prescription were associated with SBP

changes from baseline at both weeks 12 (**Figure 3A**) and 24 (**Figure 3B**). The magnitude of the SBP

reduction was strongly influenced by baseline SBP levels (**Figure 4A**), with higher baseline values

associated with greater reductions in DTx users (**Figure S10**). Moderate correlations were observed

between baseline morning home SBP measurements and those measured at week 12 (correlation

coefficient, r = 0.676) and week 24 (r = 0.544) (**Figure S11**). Regarding seasonal variation, patients

initiating the DTx in summer showed smaller SBP reduction at 24 weeks than did those initiating the DTx

in spring (reference), indicating temperature-related seasonal effects (**Figures 4B and S12**).

Association between app usage metrics and blood pressure reduction

Finally, we examined the relationship between the three app usage metrics (individual app engagement

proportion, Step 1 duration, and Step 2 duration) and SBP changes at weeks 12 and 24 (**Figure 5**).

Notably, patients with high individual app engagement (≥71.4%) achieved greater SBP reductions than

did those with low engagement (<71.4%) at both week 12 (adjusted difference, −1.7 mmHg; CI, −3.0 to

−0.43) and week 24 (−3.4 mmHg; CI, −5.1 to −1.6). Regarding program progression, a shorter Step 1

duration (<30 days) was associated with greater SBP reduction than was a longer Step 1 duration (≥30

days) at week 12 (1.9 mmHg; CI, 0.85 to 3.0) , although no such difference was observed at week 24

(0.36 mmHg; CI, -0.95 to 1.7). Similarly, patients who completed Step 2 in less than 60 days

demonstrated greater SBP reduction than did those requiring ≥60 days, with such a difference being

significant at week 24 (1.8 mmHg; CI, 0.66 to 3.0).

Discussion

The current study used a practice-based RWD cohort to evaluate blood pressure changes in patients

prescribed the DTx app for hypertension. Our results demonstrated reductions in morning home SBP from

baseline at both week 12 (−4.8 mmHg) and week 24 (−6.0 mmHg). Moreover, the DTx app conferred

realistic benefits across diverse hypertensive patient subgroups, with its effects being notable among older

adults (≥65 years) and those on medication—demographics who had been previously excluded from the

HERB-DH1 randomized controlled trial. Importantly, baseline morning home SBP levels and the season

at which DTx was initiated significantly influenced the magnitude of blood pressure reduction at both

assessment timepoints. Furthermore, higher individual app engagement proportion and more efficient

progression through the Step 1 and Step 2 programs were associated with greater reductions in morning

home SBP.

This research offers several important findings. First, our findings show that DTx certainly lowers

blood pressure in real-world scenarios, supporting the results of a recent meta-analysis by Boima et al.,

which showed that digital interventions promoted a significant reduction in SBP.[15] Moreover, our

subgroup analysis demonstrated that the DTx app induced consistent morning home SBP reductions

across subgroups, especially among patients over 65 years old and those on medication, emphasizing its

effectiveness in populations previously excluded from the HERB-DH1 trial.[7] This analysis demonstrates

the value of RWD in revealing the effectiveness of the DTx app in populations not included at the clinical

trial stage, addressing clinical questions difficult to address through randomized controlled trials alone

(e.g., the correlation between glucose status and baseline blood pressure on cardiovascular diseases from

the Japanese nationwide claims-based database[16] or first-line treatment choices and medication adherence

for hypertension management from TriNetX electronic medical records in the United States[17]).

Notably, baseline SBP and the seasonal timing of DTx initiation were identified as important

determinants of treatment response, with baseline SBP already at optimal levels and summer initiation

promoting smaller blood pressure reductions. Stratification of baseline morning home SBP values

revealed a baseline SBP-dependent linear drop in SBP, consistent with the findings of Gazit et al. on the

efficacy of a smartphone-based hypertension self-management program.[18] Despite correlations between

baseline morning home SBP and subsequent measurements, the confluence of equality and regression

lines around the optimal SBP threshold of 120 mmHg[2,3,12] demonstrates the potential of comprehensive

lifestyle improvements encouraged by the DTx app to promote optimal SBP ranges. For example, the

PREMIER study clearly demonstrated that total lifestyle adjustment impacted blood pressure in patients

with grade 1 hypertension whose average SBP approached 120 mmHg after a 6-month intervention.[19]

Conversely, patients with a baseline home morning SBP below 120 mmHg showed an increase in SBP at

12 and 24 weeks, which trended toward the 120 mmHg mark. This paradoxical effect had been reported

in a previous study showing that SBP gradually approached 120 mmHg over a 3-year period in patients

using smartphone-based hypertension self-management, beginning with normal blood pressure (SBP

<120 mmHg) at baseline.[18] Given that one of the primary mechanisms through which DTx achieves blood

pressure reduction is dietary sodium reduction,[7] our findings align with those presented in previous

research by He et al., which revealed that the blood pressure-lowering effects of salt reduction were

substantially lower in normotensive individuals than in hypertensive patients.[20] This physiological

phenomenon may explain the diminishing effectiveness of the DTx intervention as the patients' blood

pressure approaches the normotensive range. Hence, further investigations into the mechanism by which

the DTx app influences patients already in the ideal SBP range, as well as studies evaluating the long-

term effectiveness of the DTx app on cardiovascular outcomes beyond blood pressure control, are

imperative.

Regarding seasonal variation, the timing of DTx initiation was associated with morning home

SBP changes at both weeks 12 and 24, with SBP being 3.8–4.8 mmHg higher with summer initiation than

with spring initiation. Blood pressure exhibits well-established seasonal fluctuations in response to

environmental temperature as a consequence of physiological thermoregulation mechanisms.[21] Home

morning SBP typically registers 5–6 mmHg lower in summer compared to winter,[21-23] which aligns with

our findings. Given an overall DTx-mediated reduction in morning home SBP of −4.8 and −6.0 mmHg at

weeks 12 and 24, respectively, one can reasonably assume that the intervention effect for patients with

hypertension who initiated the DTx during summer was essentially neutral due to the counterbalancing

effect of this inherent seasonal variation in blood pressure.

Over 80% of the DTx users continued with the app through week 12, with two-thirds maintaining

usage for the full 24-week period. Individual app engagement proportion could be one of the important

variables for both lifestyle modification and app efficacy.[18,24,25] Although the overall DTx retention rates

were lower than those observed in well-conducted randomized controlled trials,[7] they were consistent

with those reported in previous digital intervention studies,[26] suggesting that the results obtained in the

current study were quite favorable. Furthermore, higher individual app engagement proportion and more

efficient progression through the Step 1 and Step 2 programs were associated with greater reductions in

morning home SBP. These results consistently highlighted the importance of app engagement and

expeditious completion of specific learning modules for lifestyle modification, which likely reflects

higher motivation for hypertension control, in achieving desirable blood pressure-lowering effects among

DTx users.

Blood pressure control proportions among DTx app users according to the hypertension

guidelines were encouraging, although some room for improvement is present. In particular, our study

found control proportions of 56.4%, 33.8%, and 15.9% for morning home blood pressure and 73.5%,

56.8%, and 33.1% for evening home blood pressure based on ESH 2023, ACC/AHA 2017, and JSH2019,

respectively. In this RWD cohort, hypertensive patients demonstrated reasonably good control compared

to participants of the earlier HERB-DH1 trial, who were primarily poorly controlled, with all patients

having a baseline morning home SBP exceeding 135 mmHg. The blood pressure-lowering effects of the

DTx app seem to plateau at around a home SBP level of 120 mmHg, which is clearly lower than the target

thresholds suggested by the three hypertension management guidelines (<135/85 mmHg by ESH 2023,[11]

<130/80 by ACC/AHA 2017,[12] <125/75 by JSH 2019[3]). Moreover, the J-HOP study, a recent prospective

study on home blood pressure management, showed the potential long-term benefits of stringent home

SBP control below 125/75 mmHg.[27] Nevertheless, the control levels in morning home blood pressure

achieved in the current study were suboptimal, with threshold achievement proportions of 46%, 29%, and

15% for ESH 2023, ACC/AHA 2017, and JSH 2019, respectively.[28] Although hypertension management

through the DTx app showed promise for long-term cardiovascular benefits in our practice-based RWD

cohort, these results highlight the urgent need for additional research to achieve the strict control

objectives (<125/75 mmHg) established by the JSH2019 guidelines.

The strength of our study lies in its innovative evaluation of the practical effects of an approved

and reimbursed DTx app for hypertension within a considerably large cohort. Nevertheless, certain

limitations exist, including the absence of a control group who did not use the DTx app. Moreover,

individual app engagement proportions might have been overestimated due to differences between the

latest blood pressure reading and the actual last app use. Additionally, compared to the previous pivotal

study (i.e., the HERB-DH1 trial), our study included a larger proportion of patients with normal or

elevated blood pressure due to their continued use of antihypertensive medications, which may have

attenuated the effect of the DTx app. Nevertheless, subgroup analyses based on medication status

demonstrated that the DTx app was effective for hypertension management was regardless of whether

patients were taking antihypertensive medications. Before July 27, 2023, medication usage responses may

have been inaccurately recorded given that the medication confirmation item in the app questionnaire did

not explicitly specify antihypertensive medications. Some patients might reduce or discontinue

medication in favor of using the DTx app, although this could not be certainly established from the

database alone.

In conclusion, real-world evidence obtained in the current study demonstrates that a DTx app for

hypertension management effectively reduces blood pressure across diverse patient populations in clinical

practice, particularly benefiting older adults and those on medication, expanding its therapeutic potential

beyond previously studied demographics. The significant influence of baseline SBP, seasonal factors, and

patient engagement on treatment outcomes provides crucial insights for optimizing DTx implementation

in various clinical contexts. Future research should focus on enhancing patient engagement and program

adherence as key modifiable factors for improved efficacy, ultimately supporting the broader integration

of hypertension management into daily life with DTx.

Contributions

AN, YT, and TT contributed to the conception and design of the study. YT and TT conducted data

extraction and deidentification. AN and SS contributed to the data cleaning and statistical analyses. All

authors were involved in writing the manuscript, interpreting the study findings, critically evaluating the

manuscript, and approving the final form for submission.

Declaration of interests

AN and SS received honoraria from CureApp, Inc. AN also received research grants from CureApp, Inc.

YT is a CureApp employee and may own stock. TT is one of the CureApp's board members and may own

stock. KN and KK received advisory board fees and honoraria from CureApp, Inc. MT has nothing to

disclose.

Data sharing

Direct requests for access to the data underpinning this study can be made to the corresponding author.

The data provider will jointly assess such requests.

Acknowledgments

We would like to express our gratitude to all patients and staff who participated in this study, especially to

Mitsuharu Aga, Yumi Hirayama, Fumi Hisaki, Hiroki Irisuna, and Kohta Satake for productive

discussions regarding this study. We also thank Drs. Yusuke Ohya and Katsuyuki Miura for providing

productive comments on the study results. This study was supported by CureApp, Inc. (Tokyo, Japan). In

addition, we would like to thank Enago (www.enago.jp) for the manuscript review and editing support.

During the preparation of this manuscript, Claude 3.5 and 3.7 Sonnet (Anthropic PBC, San

Francisco, USA) were used to supporting English language editing. After using this tool, we reviewed and

edited generated contents as needed and take full responsibility for the contents of the publication.

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020;76:2982-3021. doi: 10.1016/j.jacc.2020.11.010

2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021-3104. doi: 10.1093/eurheartj/ehy339

3. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). *Hypertens Res*. 2019;42:1235-1481. doi: 10.1038/s41440-019-0284-9

4. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. *BMJ*. 2013;346:f1325. doi: 10.1136/bmj.f1325

5. Kario K, Nomura A, Harada N, Tanigawa T, So R, Nakagawa K, Suzuki S, Okura A, Hida E, Satake K. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. *J Clin Hypertens (Greenwich)*. 2020;22:1713-1722. doi: 10.1111/jch.13993

6. Nomura A. Digital health, digital medicine, and digital therapeutics in cardiology: current evidence and future perspective in Japan. *Hypertens Res*. 2023;46:2126-2134. doi: 10.1038/s41440-023-01317-8

7. Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, Hida E. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. *Eur Heart J*. 2021;42:4111-4122. doi: 10.1093/eurheartj/ehab559

8. Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. *Hypertens Res*. 2022;45:1538-1548. doi: 10.1038/s41440-022-00952-x

9. Nomura A. Digital therapeutics in Japan: Present and future directions. *J Cardiol*. 2024. doi: 10.1016/j.jjcc.2024.11.005

10. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75:1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026

11. Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*. 2023;41:1874-2071. doi: 10.1097/HJH.0000000000003480

12. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,

397 Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report

398 of the American College of Cardiology/American Heart Association Task Force on Clinical Practice

399 Guidelines. *Hypertension*. 2018;71:1269-1324. doi: 10.1161/HYP.0000000000000066

400 13. Hoshide S, Yano Y, Mizuno H, Kanegae H, Kario K. Day-by-Day Variability of Home Blood Pressure and

401 Incident Cardiovascular Disease in Clinical Practice: The J-HOP Study (Japan Morning Surge-Home Blood

402 Pressure). *Hypertension*. 2018;71:177-184. doi: 10.1161/HYPERTENSIONAHA.117.10385

403 14. Narita K, Hoshide S, Kario K. Seasonal Variation in Day-by-Day Home Blood Pressure Variability and

404 Effect on Cardiovascular Disease Incidence. *Hypertension*. 2022;79:2062-2070. doi:

405 10.1161/HYPERTENSIONAHA.122.19494

406 15. Boima V, Doku A, Agyekum F, Tuglo LS, Agyemang C. Effectiveness of digital health interventions on

407 blood pressure control, lifestyle behaviours and adherence to medication in patients with hypertension in

408 low-income and middle-income countries: a systematic review and meta-analysis of randomised controlled

409 trials. *EClinicalMedicine*. 2024;69:102432. doi: 10.1016/j.eclinm.2024.102432

410 16. Yamada MH, Fujihara K, Kodama S, Sato T, Osawa T, Yaguchi Y, Yamamoto M, Kitazawa M,

411 Matsubayashi Y, Yamada T, et al. Associations of Systolic Blood Pressure and Diastolic Blood Pressure

412 With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status.

413 *Diabetes Care*. 2021;44:2124-2131. doi: 10.2337/dc20-2252

414 17. Stapff M, Hilderbrand S. First-line treatment of essential hypertension: A real-world analysis across four

415 antihypertensive treatment classes. *J Clin Hypertens (Greenwich)*. 2019;21:627-634. doi:

416 10.1111/jch.13531

417 18. Gazit T, Gutman M, Beatty AL. Assessment of Hypertension Control Among Adults Participating in a

418 Mobile Technology Blood Pressure Self-management Program. *JAMA Netw Open*. 2021;4:e2127008. doi:

419 10.1001/jamanetworkopen.2021.27008

420 19. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM,

421 Lin PH, Svetkey LP, et al. Effects of comprehensive lifestyle modification on blood pressure control: main

422 results of the PREMIER clinical trial. *JAMA*. 2003;289:2083-2093. doi: 10.1001/jama.289.16.2083

423 20. He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease:

424 JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75:632-647. doi: 10.1016/j.jacc.2019.11.055

425 21. Stergiou GS, Palatini P, Modesti PA, Asayama K, Asmar R, Bilo G, de la Sierra A, Dolan E, Head G, Kario

426 K, et al. Seasonal variation in blood pressure: Evidence, consensus and recommendations for clinical

427 practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure

428 Monitoring and Cardiovascular Variability. *J Hypertens*. 2020;38:1235-1243. doi:

429 10.1097/HJH.0000000000002341

430 22. Kollias A, Kyriakoulis KG, Stambolliu E, Ntineri A, Anagnostopoulos I, Stergiou GS. Seasonal blood

431 pressure variation assessed by different measurement methods: systematic review and meta-analysis. *J*

432 *Hypertens*. 2020;38:791-798. doi: 10.1097/HJH.0000000000002355

433   23.   Narita K, Hoshide S, Fujiwara T, Kanegae H, Kario K. Seasonal Variation of Home Blood Pressure and Its
434   Association With Target Organ Damage: The J-HOP Study (Japan Morning Surge-Home Blood Pressure).
435   *Am J Hypertens*. 2020;33:620-628. doi: 10.1093/ajh/hpaa027

436   24.   Han M, Rhee SY. Effect of Adherence to Smartphone App Use on the Long-term Effectiveness of Weight
437   Loss in Developing and OECD Countries: Retrospective Cohort Study. *JMIR Mhealth Uhealth*.
438   2021;9:e13496. doi: 10.2196/13496

439   25.   Hisaki F, Aga M, Tomitani N, Okawara Y, Harada N, Kario K. Daily self-reported behavioural efficacy
440   records on hypertension digital therapeutics as digital metrics associated with the reduction in morning
441   home blood pressure: post-hoc analysis of HERB-DH1 trial. *Hypertens Res*. 2024;47:120-127. doi:
442   10.1038/s41440-023-01434-4

443   26.   Bremer W, Sarker A. Recruitment and retention in mobile application-based intervention studies: a critical
444   synopsis of challenges and opportunities. *Inform Health Soc Care*. 2023;48:139-152. doi:
445   10.1080/17538157.2022.2082297

446   27.   Kario K, Okawara Y, Kanegae H, Hoshide S. Potential Long-Term Benefit of Home Systolic Blood
447   Pressure Below 125 mm Hg for Cardiovascular Risk Reduction: The J-HOP Study Extended. *Hypertension*.
448   2024;81:282-290. doi: 10.1161/HYPERTENSIONAHA.123.22122

449   28.   Kario K, Tomitani N, Hoshide S, Nishizawa M, Yoshida T, Kabutoya T, Fujiwara T, Mizuno H, Okawara Y,
450   Kanegae H, et al. Different Home Blood Pressure Thresholds to Predict Perfect 24-Hour Ambulatory Blood
451   Pressure Control in Treated Hypertension Based on an "All-in-One" Device. *Hypertension*. 2023;80:2464-
452   2472. doi: 10.1161/HYPERTENSIONAHA.123.21578

Figure legends

Figure 1. Schematic of this study.

Abbreviation: DTx, digital therapeutics.

Figure 2. Changes in morning home systolic blood pressure from baseline among the entire study cohort.

Abbreviations: CI, confidence interval; SBP, systolic blood pressure.

Figure 3. Subgroup changes in morning home systolic blood pressure (SBP) at weeks 12 (A) and 24 (B).

Morning home SBP reductions were consistent across subgroups except for baseline morning home SBP and seasonal distribution of digital therapeutics (DTx) prescription. Our analysis revealed the practical benefits of DTx for managing hypertension in patients aged 65 years or older and those receiving medication at baseline, which were populations specifically excluded in the previous HERB-DH1 trial.

Figure 4. Changes in morning home systolic blood pressure (SBP) from baseline according to baseline morning home SBP (A) and seasonal variation of digital therapeutics (DTx) prescription (B).

Abbreviation: MHSBP, morning home systolic blood pressure.

Figure 5. Changes in morning home systolic blood pressure from baseline according to app usage-related parameters: individual app engagement proportion (A), Step 1 duration (B), and Step 2 duration (C).

477   **Table 1. Baseline characteristics of patients in the practice-based real-world data cohort**

	Total
N	2,038
Age, mean ± SD	55.8 ± 11.4
Female, n (%)	995 (48.8)
Salt check-sheet score, median [IQR]	12 [9–16]
BMI, median [IQR]	24.5 [22.2–27.6]
Antihypertensive medication, n (%)	
Yes	823 (40.4)
No	514 (25.2)
Unknown	701 (34.4)
Baseline blood pressure (mmHg), mean ± SD	
Morning home SBP	133.5 ± 13.5
Morning home DBP	86.2 ± 10.3
Evening home SBP	129.4 ± 14.0
Evening home DBP	81.6 ± 11.1
Baseline morning home SBP category, n (%)	
<120 mmHg	288 (14.1)
120–130 mmHg	561 (27.5)
130–140 mmHg	626 (30.7)
140–150 mmHg	327 (16.0)
>150 mmHg	236 (11.6)
Seasonal distribution of DTx prescription, n (%)	
Spring (March to May)	361 (17.7)
Summer (June to August)	345 (16.9)
Autumn (September to November)	626 (30.7)
Winter (December to February)	706 (34.6)

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; IQR, interquartile range; SD,

standard deviation; RWD, real-world data; SBP, systolic blood pressure.

Figures

Figure 1.

Figure 2.

Figure 3.

A

Subgroup	N	Change from baseline (mmHg)	At week 12 (95% CI)	Adjusted difference (95% CI)
All	1645		−4.8 (−5.3 to −4.4)	
Age				
>=65	365		−5.5 (−6.5 to −4.5)	reference
<65	1280		−4.7 (−5.2 to −4.1)	1.1 (−0.0097 to 2.2)
Sex				
Male	832		−4.4 (−5.1 to −3.7)	reference
Female	813		−5.3 (−6.1 to −4.6)	−1.6 (−2.5 to −0.71)
BMI				
>=25	727		−4.9 (−5.6 to −4.1)	reference
<25	918		−4.8 (−5.5 to −4.2)	−0.73 (−1.6 to 0.20)
Salt check−sheet score				
>=14	617		−5.0 (−5.8 to −4.2)	reference
<14	932		−4.7 (−5.3 to −4.0)	−0.25 (−1.2 to 0.67)
Antihypertensive medication				
Yes	678		−4.7 (−5.6 to −3.9)	reference
No	429		−5.2 (−6.2 to −4.2)	1.4 (0.25 to 2.5)
Unknown	538		−4.7 (−5.5 to −3.9)	0.50 (−0.54 to 1.5)
Baseline morning home SBP				
Less than 120 mmHg	225		1.8 (0.75 to 2.8)	reference
120 − 130 mmHg	456		−1.3 (−2.0 to −0.61)	−3.1 (−4.5 to −1.6)
130 − 140 mmHg	510		−4.8 (−5.6 to −4.0)	−6.7 (−8.2 to−5.3)
140 − 150 mmHg	264		−9.2 (−10.3 to −8.0)	−11.4 (−13.0 to −9.8)
More than 150 mmHg	190		−15.2 (−16.9 to −13.6)	−17.1 (−18.9 to 15.4)
Season of DTx initiation				
Spring	294		−7.3 (−8.4 to −6.2)	reference
Summer	272		−1.8 (−3.0 to −0.67)	3.8 (3.6 to 7.0)
Autumn	511		−3.5 (−4.4 to −2.6)	3.4 (2.1 to 5.1)
Winter	568		−6.2 (−7.1 to −5.4)	1.5 (−0.22 to 2.7)

−20 −15 −10 −5 0 5

B

Subgroup	N	Change from baseline (mmHg)	At week 24 (95% CI)	Adjusted difference (95% CI)
All	1343		−6.0 (−6.6 to −5.4)	
Age				
>=65	298		−6.6 (−7.9 to −5.2)	reference
<65	1045		−5.8 (−6.5 to −5.1)	0.18 (−1.1 to 1.5)
Sex				
Male	679		−5.5 (−6.4 to −4.7)	reference
Female	664		−6.5 (−7.4 to −5.6)	−1.4 (−2.5 to −0.33)
BMI				
>=25	602		−5.8 (−6.7 to −4.8)	reference
<25	741		−6.2 (−7.0 to −5.4)	−1.2 (−2.3 to −0.067)
Salt check−sheet score				
>=14	517		−6.3 (−7.3 to −5.3)	reference
<14	753		−5.9 (−6.7 to −5.0)	0.018 (−1.1 to 1.1)
Antihypertensive medication				
Yes	575		−5.2 (−6.2 to −4.2)	reference
No	352		−6.8 (−8.0 to −5.6)	0.74 (−0.57 to 2.0)
Unknown	416		−6.5 (−7.6 to −5.4)	−0.65 (−1.9 to 0.59)
Baseline morning home SBP				
Less than 120 mmHg	177		3.5 (1.9 to 5.0)	reference
120 − 130 mmHg	370		−1.8 (−2.7 to −1.0)	−4.7 (−6.4 to −2.9)
130 − 140 mmHg	428		−6.0 (−6.9 to −5.1)	−8.6 (−10.3 to −6.9)
140 − 150 mmHg	216		−12.0 (−13.2 to −10.7)	−14.9 (−16.8 to −12.9)
More than 150 mmHg	152		−18.7 to (−20.9 to −16.5)	−20.9 (−23.0 to −18.8)
Season of DTx initiation				
Spring	228		−6.8 (−8.3 to −5.4)	reference
Summer	212		−0.043 (−1.6 to 1.5)	4.8 (3.0 to 6.6)
Autumn	424		−5.7 (−6.7 to −4.6)	0.63 (−0.95 to 2.2)
Winter	479		−8.5 (−9.6 to −7.5)	−1.2 (−2.8 to 0.33)

−20 −15 −10 −5 0 5

486   **Figure 4.**

487   **Figure 5.**